Essure Permanent Birth Control Will Become Standard Of Care – Conceptus
This article was originally published in The Gray Sheet
Executive Summary
Conceptus expects its Essure non-incisional permanent birth control device to replace tubal ligation for the estimated 700,000 women undergoing sterilization procedures in the U.S. annually
You may also be interested in...
Conceptus Essure Contraceptive Approved Three Months Post-Panel Review
FDA's approval of Conceptus' Essure non-incisional permanent birth control device includes a requirement that the company document the placement failure rate with newly trained physicians and identify factors associated with the failure, the agency notes in a Nov. 4 "talk paper" announcing the approval
Conceptus Essure Contraceptive Approved Three Months Post-Panel Review
FDA's approval of Conceptus' Essure non-incisional permanent birth control device includes a requirement that the company document the placement failure rate with newly trained physicians and identify factors associated with the failure, the agency notes in a Nov. 4 "talk paper" announcing the approval
Ob/Gyn Panel Reassured By Conceptus Essure Data, Recommends Caveats
Conceptus will ask FDA to drop a labeling requirement that a hysterosalpingogram (HSG) be performed three months after Essure placement, in the event that the condition accompanies approval of the non-incisional permanent birth control device